The first application of the SpiN-Tec clinical test in humans was carried out on the morning of this Friday (25), at the Faculty of Medicine of the UFMG (Federal University of Minas Gerais), in the Santa Efigênia neighborhood, in the south-central region of Belo Horizonte. Horizon. The immunizer is the first developed with national technologies and products.
The vaccine was created at CTVacinas (Vaccine Technology Center), in partnership with Fiocruz Minas (Oswaldo Cruz Foundation in Minas Gerais), and cost the institutions BRL 86 million. The immunizer was also funded by the Belo Horizonte City Hall, which passed on R$ 30 million, in 2021. The ALMG (Legislative Assembly of Minas Gerais) also financed the project with R$ 40 million, with R$ 20 million from the entity’s resources and another R$ 20 million from the agreement between Vale and the Government of Minas Gerais. The project has already gone through the stages of pre-clinical trials.
“No side effects were observed at the application site or systemic changes, such as weight loss or temperature change. In addition, excellent levels of antibodies, T lymphocyte response and protection against infection with Sars-CoV-2 were verified in laboratory animals”, said the research coordinator of the immunizer, Ricardo Gazzinelli.
According to the institution, the vaccine was developed with the joining of two proteins, S and N. offers protection against variants of the coronavirus since the N protein is less subject to mutations and is not present in other immunizers.
“This is another relevant step by Brazil towards having a national production chain of immunobiologicals. The Ministry of Science and Technology acts as a promoter of this development so that the final result of these researches can be reverted into national autonomy for its own production and meets the needs of the national health system”, says the Minister of Science, Technology and Innovations, Paulo Alvim.